Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Xu

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
Clinical and Translational Gastroenterology|December 2, 2024
Symptomatic Improvement in Adults and Adolescents with Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Clinical and Translational Gastroenterology|January 24, 2025
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
AIDS and Behavior|February 26, 2020
Social and Economic Equity and Family Cohesion as Potential Protective Factors from Depression Among Adolescents Living with HIV in UgandaPatricia Cavazos-Rehg, Christine Xu, Erin Kasson, et al.
Clinical Pharmacology in Drug Development|September 23, 2024
Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy ParticipantsChristine Xu, Kong Xin, Matthew P Kosloski, et al.
Rheumatology and Therapy|December 7, 2017
Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid ArthritisAlan Kivitz, Lydie Baret-Cormel, Hubert van Hoogstraten, et al.
Clinical Pharmacology in Drug Development|July 17, 2020
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid TumorsKen Ogasawara, Christine Xu, Jian Yin, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2020
Excretion balance and pharmacokinetics following a single oral dose of [<sup>14</sup>C]-fedratinib in healthy subjectsKen Ogasawara, Christine Xu, Vanaja Kanamaluru, et al.
Clinical Pharmacokinetics|October 11, 2016
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid ArthritisEun Bong Lee, Nikki Daskalakis, Christine Xu, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteersMeng Zhang, Christine Xu, Lei Ma, et al.
Modern Rheumatology|December 16, 2021
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trialsYoshiya Tanaka, Toshiya Takahashi, Mariko Sumi, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
Clinical and Translational Gastroenterology|December 2, 2024
Symptomatic Improvement in Adults and Adolescents with Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
Clinical and Translational Gastroenterology|January 24, 2025
Symptomatic Improvement in Adults and Adolescents With Eosinophilic Esophagitis Requires Higher Systemic Dupilumab Exposure Than Histologic ResponseEvan S Dellon, Matthew P Kosloski, Arsalan Shabbir, et al.
AIDS and Behavior|February 26, 2020
Social and Economic Equity and Family Cohesion as Potential Protective Factors from Depression Among Adolescents Living with HIV in UgandaPatricia Cavazos-Rehg, Christine Xu, Erin Kasson, et al.
Clinical Pharmacology in Drug Development|September 23, 2024
Pharmacokinetics of Subcutaneous Itepekimab Injection With an Autoinjector Device and Prefilled Syringe in Healthy ParticipantsChristine Xu, Kong Xin, Matthew P Kosloski, et al.
Rheumatology and Therapy|December 7, 2017
Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid ArthritisAlan Kivitz, Lydie Baret-Cormel, Hubert van Hoogstraten, et al.
Clinical Pharmacology in Drug Development|July 17, 2020
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid TumorsKen Ogasawara, Christine Xu, Jian Yin, et al.
Cancer Chemotherapy and Pharmacology|August 5, 2020
Excretion balance and pharmacokinetics following a single oral dose of [<sup>14</sup>C]-fedratinib in healthy subjectsKen Ogasawara, Christine Xu, Vanaja Kanamaluru, et al.
Clinical Pharmacokinetics|October 11, 2016
Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid ArthritisEun Bong Lee, Nikki Daskalakis, Christine Xu, et al.
Clinical Pharmacology in Drug Development|May 4, 2016
Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteersMeng Zhang, Christine Xu, Lei Ma, et al.
Modern Rheumatology|December 16, 2021
Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trialsYoshiya Tanaka, Toshiya Takahashi, Mariko Sumi, et al.
Pageof 8